How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
53
TRIB Quote, Financials, Valuation and Earnings
Last price:
$0.87
Seasonality move
:
-1.26%
Day range:
$0.88 - $0.93
52-week range:
$0.48 - $3.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.32x
P/B ratio:
--
Volume:
129K
Avg. volume:
6.5M
1-year change:
-33.29%
Market cap:
$16.9M
Revenue:
$61.4M
EPS (TTM):
-$2.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRIB
Trinity Biotech Plc
|
$7.5M | -$0.57 | -33.73% | -28.57% | -- |
|
AKTX
Akari Therapeutics Plc
|
-- | -$0.06 | -- | -53.67% | $3.53 |
|
AMRN
Amarin Corp. Plc
|
$50.6M | $0.07 | -18% | -100% | $12.00 |
|
ASND
Ascendis Pharma A/S
|
$293.9M | -$0.28 | 204.11% | -54.05% | $278.98 |
|
CLLS
Cellectis SA
|
$11.9M | -$0.11 | -5.7% | -56.58% | $7.00 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.22 | -- | -86.12% | $39.69 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech Plc
|
$0.91 | -- | $16.9M | -- | $0.00 | 0% | 0.32x |
|
AKTX
Akari Therapeutics Plc
|
$0.25 | $3.53 | $9.1M | -- | $0.00 | 0% | -- |
|
AMRN
Amarin Corp. Plc
|
$15.03 | $12.00 | $312.5M | -- | $0.00 | 0% | 7.84x |
|
ASND
Ascendis Pharma A/S
|
$222.45 | $278.98 | $13.6B | -- | $0.00 | 0% | 18.60x |
|
CLLS
Cellectis SA
|
$4.06 | $7.00 | $407.3M | -- | $0.00 | 0% | 5.05x |
|
DBVT
DBV Technologies SA
|
$23.77 | $39.69 | $650.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRIB
Trinity Biotech Plc
|
147.47% | 0.730 | 785.94% | 0.87x |
|
AKTX
Akari Therapeutics Plc
|
8.54% | -2.274 | 6.43% | 0.16x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 3.053 | 1.98% | 2.35x |
|
ASND
Ascendis Pharma A/S
|
127.22% | -0.633 | 7.87% | 0.68x |
|
CLLS
Cellectis SA
|
54.27% | 0.076 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.671 | 5.85% | 1.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech Plc
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.2M | -82.27% | -91.86% | -- | -$2.1M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
ASND
Ascendis Pharma A/S
|
$219.4M | $12.9M | -34.4% | -880.05% | 5.15% | $1.3M |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
Trinity Biotech Plc vs. Competitors
-
Which has Higher Returns TRIB or AKTX?
Akari Therapeutics Plc has a net margin of -31.41% compared to Trinity Biotech Plc's net margin of --. Trinity Biotech Plc's return on equity of -- beat Akari Therapeutics Plc's return on equity of -91.86%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M AKTXAkari Therapeutics Plc-- -$0.19 $24.8M -
What do Analysts Say About TRIB or AKTX?
Trinity Biotech Plc has a consensus price target of --, signalling upside risk potential of 1553.44%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $3.53 which suggests that it could grow by 1291.08%. Given that Trinity Biotech Plc has higher upside potential than Akari Therapeutics Plc, analysts believe Trinity Biotech Plc is more attractive than Akari Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech Plc0 0 0 AKTXAkari Therapeutics Plc2 0 0 -
Is TRIB or AKTX More Risky?
Trinity Biotech Plc has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.272, suggesting its less volatile than the S&P 500 by 72.768%.
-
Which is a Better Dividend Stock TRIB or AKTX?
Trinity Biotech Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech Plc pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or AKTX?
Trinity Biotech Plc quarterly revenues are $15.2M, which are larger than Akari Therapeutics Plc quarterly revenues of --. Trinity Biotech Plc's net income of -$4.8M is higher than Akari Therapeutics Plc's net income of -$6.4M. Notably, Trinity Biotech Plc's price-to-earnings ratio is -- while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech Plc is 0.32x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech Plc0.32x -- $15.2M -$4.8M AKTXAkari Therapeutics Plc-- -- -- -$6.4M
-
Which has Higher Returns TRIB or AMRN?
Amarin Corp. Plc has a net margin of -31.41% compared to Trinity Biotech Plc's net margin of -15.58%. Trinity Biotech Plc's return on equity of -- beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About TRIB or AMRN?
Trinity Biotech Plc has a consensus price target of --, signalling upside risk potential of 1553.44%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -23.52%. Given that Trinity Biotech Plc has higher upside potential than Amarin Corp. Plc, analysts believe Trinity Biotech Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech Plc0 0 0 AMRNAmarin Corp. Plc0 1 1 -
Is TRIB or AMRN More Risky?
Trinity Biotech Plc has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.8%.
-
Which is a Better Dividend Stock TRIB or AMRN?
Trinity Biotech Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or AMRN?
Trinity Biotech Plc quarterly revenues are $15.2M, which are smaller than Amarin Corp. Plc quarterly revenues of $49.4M. Trinity Biotech Plc's net income of -$4.8M is higher than Amarin Corp. Plc's net income of -$7.7M. Notably, Trinity Biotech Plc's price-to-earnings ratio is -- while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech Plc is 0.32x versus 7.84x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech Plc0.32x -- $15.2M -$4.8M AMRNAmarin Corp. Plc7.84x -- $49.4M -$7.7M
-
Which has Higher Returns TRIB or ASND?
Ascendis Pharma A/S has a net margin of -31.41% compared to Trinity Biotech Plc's net margin of -28.55%. Trinity Biotech Plc's return on equity of -- beat Ascendis Pharma A/S's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M ASNDAscendis Pharma A/S87.87% -$1.17 $751.5M -
What do Analysts Say About TRIB or ASND?
Trinity Biotech Plc has a consensus price target of --, signalling upside risk potential of 1553.44%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $278.98 which suggests that it could grow by 25.41%. Given that Trinity Biotech Plc has higher upside potential than Ascendis Pharma A/S, analysts believe Trinity Biotech Plc is more attractive than Ascendis Pharma A/S.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech Plc0 0 0 ASNDAscendis Pharma A/S13 0 0 -
Is TRIB or ASND More Risky?
Trinity Biotech Plc has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.4%.
-
Which is a Better Dividend Stock TRIB or ASND?
Trinity Biotech Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech Plc pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or ASND?
Trinity Biotech Plc quarterly revenues are $15.2M, which are smaller than Ascendis Pharma A/S quarterly revenues of $249.6M. Trinity Biotech Plc's net income of -$4.8M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, Trinity Biotech Plc's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech Plc is 0.32x versus 18.60x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech Plc0.32x -- $15.2M -$4.8M ASNDAscendis Pharma A/S18.60x -- $249.6M -$71.3M
-
Which has Higher Returns TRIB or CLLS?
Cellectis SA has a net margin of -31.41% compared to Trinity Biotech Plc's net margin of 1.68%. Trinity Biotech Plc's return on equity of -- beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About TRIB or CLLS?
Trinity Biotech Plc has a consensus price target of --, signalling upside risk potential of 1553.44%. On the other hand Cellectis SA has an analysts' consensus of $7.00 which suggests that it could grow by 72.41%. Given that Trinity Biotech Plc has higher upside potential than Cellectis SA, analysts believe Trinity Biotech Plc is more attractive than Cellectis SA.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech Plc0 0 0 CLLSCellectis SA2 2 0 -
Is TRIB or CLLS More Risky?
Trinity Biotech Plc has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.823, suggesting its more volatile than the S&P 500 by 182.278%.
-
Which is a Better Dividend Stock TRIB or CLLS?
Trinity Biotech Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech Plc pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or CLLS?
Trinity Biotech Plc quarterly revenues are $15.2M, which are smaller than Cellectis SA quarterly revenues of $35M. Trinity Biotech Plc's net income of -$4.8M is lower than Cellectis SA's net income of $586.4K. Notably, Trinity Biotech Plc's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech Plc is 0.32x versus 5.05x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech Plc0.32x -- $15.2M -$4.8M CLLSCellectis SA5.05x -- $35M $586.4K
-
Which has Higher Returns TRIB or DBVT?
DBV Technologies SA has a net margin of -31.41% compared to Trinity Biotech Plc's net margin of --. Trinity Biotech Plc's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About TRIB or DBVT?
Trinity Biotech Plc has a consensus price target of --, signalling upside risk potential of 1553.44%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 66.7%. Given that Trinity Biotech Plc has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech Plc0 0 0 DBVTDBV Technologies SA4 0 1 -
Is TRIB or DBVT More Risky?
Trinity Biotech Plc has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.
-
Which is a Better Dividend Stock TRIB or DBVT?
Trinity Biotech Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or DBVT?
Trinity Biotech Plc quarterly revenues are $15.2M, which are larger than DBV Technologies SA quarterly revenues of --. Trinity Biotech Plc's net income of -$4.8M is higher than DBV Technologies SA's net income of -$33M. Notably, Trinity Biotech Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech Plc is 0.32x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech Plc0.32x -- $15.2M -$4.8M DBVTDBV Technologies SA-- -- -- -$33M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
